Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06587282 · ClinicalTrials.gov registry record · NA

PREEMIE: Study for Treatment of PDA in Premature Infants

A NA study of Patent Ductus Arteriosus (PDA), sponsored by Merit Medical Systems.

Recruiting
Registry status
NA
Development phase
55
Enrollment target
10
Study locations

NCT06587282 is a NA study of Patent Ductus Arteriosus (PDA) that is actively recruiting participants, run by Merit Medical Systems. The registered enrollment target is 55 participants. The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06587282, a NA study of Patent Ductus Arteriosus (PDA), is actively recruiting participants, sponsored by Merit Medical Systems.

RECRUITING
Registry status
NA
Development phase
55 participants
Enrollment target
10
Study locations

Study Summary

This multicenter, single arm, prospective, non-randomized study is designed to evaluate the safety and effectiveness of The Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in pre-mature infants over a period of 6 months.

Interventions

  • DEVICE Bloom Micro Occluder System

Study Locations (10)

California

  • UC Davis Health - Sacramento
  • UC San Diego-Rady Children's Hospital - San Diego

Florida

  • Memorial Healthcare System-Joe DiMaggio Children's Hospital - Hollywood
  • Nicklaus Children's Hospital - Miami

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Missouri

  • Washington University-St. Louis Children's Hospital - St Louis

Ohio

  • Nationwide Children's Hospital - Columbus

Tennessee

  • Le Bonheur Children's Hospital - Memphis

Texas

  • UT Southwestern Medical Center - Dallas

Wisconsin

  • Herma Heart Institute-Children's Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2025-03-06
Est. Completion 2029-03
Phase NA

Sponsor

Merit Medical Systems

18 total trials

What the Registry Record Tells You About NCT06587282

The ClinicalTrials.gov registry entry for NCT06587282 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merit Medical Systems, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Patent Ductus Arteriosus (PDA) appearing as the primary indexed condition, and to 1 intervention - of which Bloom Micro Occluder System is the first listed.

NCT06587282 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06587282 about?

NCT06587282 is a clinical study titled "PREEMIE: Study for Treatment of PDA in Premature Infants". This multicenter, single arm, prospective, non-randomized study is designed to evaluate the safety and effectiveness of The Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in pre-mature infants over a period of 6 months.

What is the current status of trial NCT06587282?

This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2025-03-06. Estimated completion is 2029-03.

What conditions does trial NCT06587282 study?

This clinical trial studies the following conditions: Patent Ductus Arteriosus (PDA).

What interventions are being tested in trial NCT06587282?

The interventions under investigation include: Bloom Micro Occluder System (DEVICE).

Who is sponsoring clinical trial NCT06587282?

This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06587282 being conducted?

This trial has 10 study locations across California, Florida, Georgia, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.